Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Perspective of SGLT2 inhibition in treatment of conditions connected to neuronal loss: focus on alzheimer's disease and ischemia-related brain injury
Studies with complete reporting and rigorous design were rated as "High," while others with some limitations or missing methodological details were rated as "Medium" or "Low." To evaluate the reliability and scientific rigor of the evidence presented in this review, we conducted a methodological quality assessment of the primary clinical trials included
Lappin JM et al
Authors contributions Drafting the manuscript, creating figures and tables (WMW), and critically revising the document for important intellectual content (LGL)
US$ 27.22
US$ 27.63
US$ 24.00
US$ 21.10
US$ 20.17
US$ 21.76
US$ 27.80
